May 19, 2009.....
After GSK now it is time for Takeda Pharmaceutical, Takeda is Japan's largest drug maker, and it said that it's US subsidiary is going to acquire U.S.-based IDM Pharma for $75 million, to make its presence felt in the cancer drug market.It has taken the responsibility for MEPACT®, IDM Pharma's biggest prize and Takeda US will be responsible for commercializing MEPACT in Europe.
May 18, 2009......
GlaxoSmithKline strategic alliance with Oxford Bio Therapeutics to develop novel cancer antibodies, with this deal Oxford bio therapeutics will be eligible for total $ 370 Million after achieving specified discovery, development, regulatory and commercialisation milestones.
May 15, 2009...........
GlobeImmune, Inc. and Celgene Corporation last week announced a strategic collaboration focused in area of drug discovery, development and commercialization of multiple product candidates based on powerful, targeted therapy for treatment of cancer. GlobeImmune will be eligible to receive over $500 million in development and regulatory milestones, with royalties and additional milestone payments based on the sales of licensed drug candidates.
No comments:
Post a Comment